Medical research is the promise that soon we will discover something new that will ease the burden, restore health and ultimately cure disease. At the American Lung Association, this promise is fulfilled every year as our research continues to unlock the secrets of asthma, COPD, lung cancer and more, in ways that have a direct, life-changing impact on patients' lives.
In the past fiscal year, the American Lung Association devoted $9 million to lung disease research, supporting 85 novel and innovative research projects. In connection with our LUNG FORCE initiative to fight lung cancer, we dedicated $1.6 million to lung cancer research. This represents a 50 percent increase over the prior year in research spending to combat the leading cause of cancer-related death in the United States.
This past year, our Airways Clinical Research Centers Network (ACRC) expanded its research to include COPD and has launched two new initial studies: Anxiety and COPD Evaluation (ACE) and Resistant Airway Obstruction in Children (REACH).
The initial results of our Study of Soy Isoflavones in Asthma (SOYA) were reported at the American Thoracic Society Annual Meeting and in the Journal of the American Medical Association. Soy isoflavones are a dietary supplement many people take with the belief that they help relieve asthma symptoms. However, our study did not find evidence of symptom improvement in patients taking soy isoflavones, suggesting that patients may be buying and taking an unnecessary and ineffective supplement. See how our ACRC asthma and COPD studies change lives and support patients by improving disease management.
In support of our ongoing focus on lung cancer, we published "Providing Guidance on Lung Cancer Screening to Patients and Physicians." This important update from the American Lung Association Lung Cancer Screening Committee contains updated recommendations about low-dose CT screening for lung cancer and strong recommendations that assessment of smoking history and provision of smoking cessation services must be part of any lung cancer screening program.
We also signed an agreement with the Foundation for the National Institutes of Health (FNIH) to help support the Lung-MAP project, a groundbreaking, collaborative approach to clinical trial in squamous cell lung cancer that brings together the National Cancer Institute, SWOG Cancer Research, the FNIH, Friends of Cancer Research, pharmaceutical companies and eight advocacy partners.
Meet some of our researchers and share their passion for beating lung disease.
If you would like to support the work of the American Lung Association, please donate today.